IDH1 and acute myeloid leukemia: Then DiNardo et al. reported that ivosidenib, a small-molecule inhibitor of IDH1, promoted durable remission and molecular remission in patients with CR in a phase 1 clinical trial of patients with advanced IDH1-mutant relapsed/refractory AML (96).